Available research suggests DSIP doesn't cause dependence
Clinical trial data show nausea is common across GLP-1 therapies, regardless of routeranging from 11%20% with oral Rybelsus and up to 47% with oral Wegovy (25 mg), to 44% with injectable Wegovy and 12%18% with injectable Mounjaro
Prolines of BPC157 were labeled with [ 3 H] and the structure of [ 3 H]-labeled BPC157 is shown in Figure 3A
3 Administration methods (IM or IV) can affect how the compound is processed in the body
When GLP-1 binds to receptors in these areas, it activates anorexigenic (appetite-suppressing) neurons whilst inhibiting orexigenic (appetite-stimulating) pathways, contributing to reduced food intake and increased satiety
However, before those trials can move forward, Judge Marston has ordered both sides to resolve several issues that could have broad implications for the litigation, including preemption and general causation